Decreased proliferative capacity of entrectinib treated NB cells was confirmed by evaluating Ki-67 nuclear antigen, an important marker of cell proliferation [16], by Real Time quantitative PCR (qRT-PCR). This evidence concerns the gene MKI67 and neuroblastoma.